{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:48:20Z","timestamp":1740134900020,"version":"3.37.3"},"reference-count":4,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,18]]},"DOI":"10.1182\/blood.2024024790","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T15:31:01Z","timestamp":1721316661000},"page":"243-244","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of relapsed CLL \u201cin the BAAG\u201d?"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0308-6458","authenticated-orcid":false,"given":"Stephen","family":"Opat","sequence":"first","affiliation":[{"name":"Monash University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"3","key":"2024071815305688000_bib1","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.2023022730","article-title":"Acalabrutinib, venetoclax, and obinutuzumab in relapsed\/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial","volume":"144","author":"F\u00fcrstenau","year":"2024","journal-title":"Blood"},{"issue":"8","key":"2024071815305688000_bib2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2024071815305688000_bib3","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased\u00a0variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"4","key":"2024071815305688000_bib4","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/leu.2015.313","article-title":"A\u00a0complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study","volume":"30","author":"Rawstron","year":"2016","journal-title":"Leukemia"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/3\/243\/2234585\/blood_bld-2024-024790-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/3\/243\/2234585\/blood_bld-2024-024790-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T15:31:05Z","timestamp":1721316665000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/3\/243\/516959\/Treatment-of-relapsed-CLL-in-the-BAAG"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":4,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024790","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2024,7,18]]}}}